Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds

Sunshine Biopharma Inc.

Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.
Potential additional $12.0M if Series C warrants fully exercised; no assurance given.
Net proceeds for general corporate purposes and working capital.
Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at approximately $6 million (effective 2026-05-18).

Action: entry
Agreement: underwriting
Counterparty: Aegis Capital Corp.
Value: approximately $6 million
Effective: 2026-05-18

Exact text from the filing

On May 18, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering

View on SEC.gov

Browse all material agreements →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-004116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.